Skip to main content
Clinical Trials/NCT05516953
NCT05516953
Completed
Phase 2

Clinical Study Evaluating the Efficacy of Baclofen in Preventing Postoperative Nausea and Vomiting After Laparoscopic Sleeve Gastrectomy

Tanta University1 site in 1 country100 target enrollmentAugust 22, 2022

Overview

Phase
Phase 2
Intervention
Baclofen Tablets
Conditions
Postoperative Nausea and Vomiting
Sponsor
Tanta University
Enrollment
100
Locations
1
Primary Endpoint
The primary outcome of this study will be the complete response
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study aims to evaluate the possible efficacy of baclofen on postoperative nausea and vomiting in patient with morbid obesity who will undergo laparoscopic sleeve gastrectomy.

Detailed Description

. A total of 100 morbidly obese patients who will be scheduled for sleeve gastrectomy will be included in the study. The patients will be selected from those attending Gastrointestinal and Laparoscopic Surgery Unit, General Surgery Department, Tanta University Hospital, Tanta, Egypt. The participants will be randomized into four groups by closed envelop method

Registry
clinicaltrials.gov
Start Date
August 22, 2022
End Date
February 28, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Aya Gamal Moussa

Assistant Lecturer at Clinical Pharmacy department , Faculty of Pharmacy -Tanta University

Tanta University

Eligibility Criteria

Inclusion Criteria

  • Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥35 kg/m2 with the presence of comorbidity such as hypertension, arthritis, and diabetes.
  • Morbidly obese patients scheduled for sleeve gastrectomy with BMI ≥ 40 kg/m2 without comorbidity.
  • Patients fit for anesthesia and surgery.

Exclusion Criteria

  • Patients with BMI \>55 kg/m
  • Patients with previous procedures for the treatment of obesity.
  • Pregnant females and lactating women.
  • Patients with psychological or psychiatric disease
  • Administration of antiemetic medication or systemic corticosteroids within 24 hours before surgery
  • Patients who experienced vomiting within 24 hours before surgery.
  • Patients with history of alcohol or drug abuse.
  • Patients with hypersensitivity or contraindications to any of the drugs used in this study.

Arms & Interventions

Group 2

which include 50 patients scheduled for sleeve gastrectomy

Intervention: Baclofen Tablets

Outcomes

Primary Outcomes

The primary outcome of this study will be the complete response

Time Frame: The first 48 hours after surgery.

Complete response is defined as the absence of PONV and the lack of a need for rescue antiemetic therapy.

Secondary Outcomes

  • Change in serum level of vasopressin(The first 48 hours after surgery.)
  • Change in serum level of serotonin(The first 48 hours after surgery.)
  • Change in serum level of tachykinin 1(The first 48 hours after surgery.)
  • Change in serum level of substance P(The first 48 hours after surgery.)
  • Change in serum level of dopamine(The first 48 hours after surgery.)

Study Sites (1)

Loading locations...

Similar Trials